Frequency Therapeutics, Inc. Loss Submission Form

Company: Frequency Therapeutics, Inc.

Ticker: (NASDAQ) FREQ

Deadline

Passed

Lead Plaintiff Deadline: August 02, 2021

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines.

Scan the QR code or click the button to join.

Join on WhatsApp

Get Updates by Email

Subscribe for email notifications.

Full Name

No spam, opt-out anytime, alert list is free.

Allegations

the Company’s Phase 2a trial results failed to live up to the Company’s expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322’s potential. These statements materially misled the market and artificially inflated the value of Frequency’s common stock.